Clinical Trial: Gemcitabine in NK/T Cell Lymphoma

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma

Brief Summary: We retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen

Detailed Summary:
Sponsor: Samsung Medical Center

Current Primary Outcome: Overall response rate [ Time Frame: 2012-May ]

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Samsung Medical Center

Dates:
Date Received: August 6, 2012
Date Started: August 2012
Date Completion:
Last Updated: February 11, 2013
Last Verified: August 2012